Oxford, 3 January 2013 Chroma Therapeutics Limited announced today that GlaxoSmithKline (GSK) has approved the progression of Chromas novel macrophage-targeted HDAC inhibitor, CHR-5154, towards human…
LONDON, Jan 3 (Reuters) - Chroma Therapeutics Ltd: * Chroma Therapeutics extends collaboration with gsk, and advancesnovel…
SAN DIEGO, Dec. 21, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Pfizer Inc. (NYSE: PFE…
Shares of Halozyme Therapeutics soared 30 on 21 December after it revealed it had inked a worldwide deal with Pfizer to develop and commercialize subcutaneous biologics using recombinant human hyaluro…
